Therapy assessment in prostate cancer using imaging surrogate markers for the PI3K-AKT-mTORC- and AR-pathway (B11*)

点击翻译按钮获取中文摘要

Recurrent prostate cancer commonly being treated with different androgen-receptor(AR)-modulating agents is highly expressing the prostate-specific-membrane-antigen (PSMA) constituting an ideal target for imaging and radioligand therapy. The primary aim of this project is to investigate PSMA-ligand PET as potential surrogate marker for activity of the PI3K-AKT-mTORC and AR-receptor axis and to develop and evaluate probes for differentiation of androgen-dependent (AD) and CRPC (κ-opioid receptor agonists, Prostatic Acid Phosphatase). Potential pre-targeting of PSMA under AR-targeted therapy as well as additive effect of radiosensitizer on PSMA radioligand therapy will be assessed.